Synaptic abnormalities are a cardinal feature of Alzheimer's disease (AD) that are known to
arise as the disease progresses. A growing body of evidence suggests that pathological …

Metabotropic glutamate receptor 5 (mGluR5) is ubiquitously expressed in brain regions
responsible for memory and learning. It plays a key role in modulating rapid changes in …

Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a large
amount of time and resources with largely negative results. Repurposing drugs already …

Alzheimer's disease (AD) is an age-related dementia and neurodegenerative disorder,
characterized by Aβ and tau protein deposition impairing learning, memory and suppressing …

The prevalence, presentation, and progression of Alzheimer's disease (AD) differ between
men and women, although β-amyloid (Aβ) deposition is a pathological hallmark of AD in …

Alzheimer's disease (AD) is an age-related progressive neurodegenerative disorder that
leads to cognitive impairment and memory loss. Emerging evidence suggests that …

Here an overview is provided on therapeutic/neuroprotective effects of Lithium (Li+) in
neurodegenerative and psychiatric disorders focusing on the conspicuous action of Li+ …

The type 5 metabotropic glutamate receptor, mGlu5, has been proposed as a potential
therapeutic target for the treatment of several neurodegenerative diseases. In preclinical …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease and is
characterized by a progressive cognitive decline in affected individuals. Current therapeutic …

Huntington's disease (HD) is an inherited autosomal dominant neurodegenerative disorder
that leads to progressive motor and cognitive impairment. There are currently no available …